www.propanc.com Open in urlscan Pro
3.124.221.80  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * Home
 * About
   * Overview
   * Mission and Vision
   * Market Need
   * Propanc Difference
   * Management Team
   * Board of Directors
   * Scientific Advisors
 * Product Pipeline
   * Overview
   * PRP
 * Technology
 * News & Media
   * Press Releases
   * Publications
   * Videos
   * In The News
 * Investors
    * Investor Relations
    * Overview
   
    * News / Events
    * News / Events
    * Press Releases
    * Presentations
    * IR Calendar
    * Email Alerts
   
    * Company Info
    * Company Information
    * Profile
    * Management Team
    * Contacts
    * FAQ
   
    * Financial Info
    * Financial Information
    * Financials
    * Financial Results
   
    * Stock Data
    * Stock Data
    * Quote
    * Charts
    * Historical Data
   
    * SEC Filings
    * SEC Filings
    * All SEC Filings
    * Annual Reports
    * Quarterly Reports
    * Section 16 Filings
   
    * Governance
    * Corporate Governance
    * Board of Directors
    * Board Committees
    * Governance Documents

 * Contact


OFFERING NEW HOPE TO CANCER PATIENTS AND THEIR CAREGIVERS



A New Frontier in Cancer Therapy
What makes us a life-changing biotech


TECHNOLOGY BASED ON PANCREATIC ENZYME THERAPY

Our long-term therapy is based on a pancreatic proenzyme formulation that
suppresses tumor recurrence and metastasis.

How Our Technology Works


HALTING CANCER CELLS’ ABILITY TO INVADE AND METASTASIZE

PRP, our lead candidate, controls cancer cell migration, inhibits tumor blood
vessel formation and triggers the cell’s death.

How PRP Works


LATEST DEVELOPMENTS

Propanc Biopharma Initiates Development of Bio-Analytical Assay in Preparation
for Human Trials

Learn More

Propanc Biopharma Commences Drug Discovery Research Collaboration

Learn More


SIGNIFICANT MARKET OPPORTUNITY FOR CANCER THERAPY

80% of all cancers are solid tumors. We are initially targeting pancreatic,
ovarian and colorectal tumors.

View the market need for solid tumors


LATEST NEWS

Nov 15, 2022

Propanc Biopharma’s CSO Predicts PRP Could Enhance Therapeutic Effects of Immune
Checkpoint Therapy for Pancreatic Cancer
View All Press Releases


UPCOMING EVENT

Dec 15–December 17, 2022
43rd Meeting of the European Organization of Research and Treatment of Cancer
(EORTC), Pharmacology and Molecular Mechanisms (PAMM) group
View All Events


STOCK INFORMATIONNOV 22, 2022 • 3:58 PM EST | VIEW DETAILED STOCK INFO

OTCQB: PPCB Propanc Biopharma, Inc.
$0.00 Price
0.00 (16.67%) Change
126.28m Volume
0.00 - 0.00 Day Range
0.00 - 0.04 52 Week Range


INVESTOR PRESENTATION

View Investor Presentation



GET EMAIL ALERTS

Stay informed about our latest news and updates

Sign Up Today
Privacy Policy Disclaimer Sitemap ©2022 Propanc Biopharma, Inc.
2:00









2:00